Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HALOS: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION582 in Patients With Angelman Syndrome

NCT05127226 is registered in ClinicalTrials.gov with Ionis Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05127226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05127226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HALOS: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION582 in Patients With Angelman Syndrome
Lead sponsor
Ionis Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
December 22, 2021
Completion date
March 31, 2029
Enrollment
71 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

angelman syndrome